LOGIN

Indian Pharmaceuticals Industry Analysis

India's domestic pharmaceutical market is projected to grow from US$ 60 billion in FY26 to US$ 130 billion by 2030.

Advantage India

Cost
Efficiency

* India’s pharmaceutical sector is improving cost efficiency through strong policy support and technology adoption. A government release dated February 2, 2026, announced the Biopharma SHAKTI initiative (Rs. 10,000 crore) to boost domestic biopharma capabilities, reduce import dependence, and enhance efficiency.

* Additionally, as of February 17, 2026, Indian drugmakers are increasingly using AI in R&D to lower costs and shorten drug development timelines, strengthening productivity and global competitiveness.

* India's cost-efficient pharmaceutical manufacturing, backed by a skilled workforce and affordable pricing, enables the global supply of high-quality medicines, strengthening its position as the "Pharmacy of the World."

Robust economic growth icon

Economic
Drivers

*The Economic Survey 2025-26 (January 29, 2026) notes India as the third-largest producer by volume, with exports reaching US$ 30.5 billion in FY25, supported by policy push, market diversification, and stronger manufacturing.

*In FY26, India's domestic pharmaceutical market was valued at Rs. 5.30 lakh crore (US$ 60 billion).

*The pharmaceutical industry’s total turnover stood at Rs. 2,25,000 crore (US$ 26.26 billion) in FY25 lead by cardiac, gastrointestinal and anti-diabetic segments.

*India's domestic pharmaceutical market, in FY26 valued at Rs. 5.30 lakh crore (US$ 60 billion), is projected to more than double to Rs. 12.47 lakh crore (US$ 130 billion) by 2030, driven by strong manufacturing capabilities, expanding exports, policy support and India's leadership in generic medicines and vaccines.

Attractive investment icon India

Policy
Support

*PLI scheme: Rs. 15,000 crore (US$ 2.04 billion) outlay (2020-21 to 2028-29) to boost manufacturing, investment, and product diversification.

*On December 5, 2025, India announced a Rs. 60,000 crore (US$ 7 billion) API-push to boost domestic pharmaceutical manufacturing and cut import dependence.

*Under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana, 16,912 Jan Aushadhi Kendras are operational as of June 30, 2025, with a target of 25,000 by March 2027, offering 2,110 medicines and 315 devices/consumables to promote affordable quality generic healthcare.

*Government disbursed Rs. 604 crore (US$ 69.76 million) under the PLI scheme in H1 FY25.

*The article (January 16, 2026) states that policy reforms like GST 2.0 and revised Schedule M are boosting efficiency and quality, supporting India’s pharma growth, with the sector expected to expand 7–9% in 2026.

India policy support icon

Increasing
Investment

*FDI policy: Up to 100% FDI allowed via automatic route for Greenfield pharma projects; up to 74% for Brownfield via automatic, beyond that with government approval.

*The Drugs & Pharmaceuticals sector received FDI inflow of Rs. 1,59,102.60 crore (US$ 25.33 billion) from April 2000-March 2026.

*Union Budget 2025-26: Allocation of Rs. 5,268 crore (US$ 602 million) for the Department of Pharmaceuticals, up 28.8% over previous budget estimates.

*The PIB press note dated February 02, 2026, announces Rs. 10,000 crore (US$ 1.08 billion) Biopharma SHAKTI investments to boost R&D, biologics, and clinical infrastructure, strengthening India’s pharmaceutical sector and global leadership.

*On August 8, 2026, India’s pharmaceutical industry emerged as a major corporate R&D investor, with drug and pharma companies spending Rs. 25,847 crore (US$ 3.12 billion) on research in 2023-24. Pharmaceuticals also ranked among India’s most research-intensive industries, highlighting strong innovation momentum.

Competitive advantage icon India
Last updated: Aug, 2026

Major states for Pharmaceuticals

  • Karnataka
  • Maharashtra
  • Gujarat
  • Uttar Pradesh
  • Delhi NCR
  • Tamil Nadu
  • Telangana
Pharmaceutical India Cluster 11 03 2022

Posters

MORE
FULFILLING GLOBAL DEMAND

FULFILLING GLOBAL DEMAND

India is the largest producer of generic drugs in the world.

IBEF Campaigns

MORE
Bharat Mobility 2027

Bharat Mobility 2027

The Bharat Mobility Global Expo 2027 04 - 09 February 2027, Bharat Manda...

Discover India

Discover India

A campaign designed to showcase the country’s rich heritage, vibrant ...

Case Studies

MORE

Containerisation: Transforming India's Maritime Trade

Containerisation: Transforming India's Maritime Trade

Despite other modes of transportation, the maritime shipping mode is the backbone of international trade. The concept of containerisation has revoluti...

India’s Growing Senior Care Needs: New Businesses and Services

India’s Growing Senior Care Needs: New Businesses and Services

The current state of India is characterised by the process of demographic transition with gradual growth of the proportion of senior citizens within t...

The Rise of India's Pathology Laboratories: Strengthening Quality and Safety in Healthcare

The Rise of India's Pathology Laboratories: Strengthening Quality and Safety in Healthcare

India has seen its healthcare system witness an impressive evolution in the last two decades because of the growth in healthcare infrastructure, incre...

IBEF BLOG

MORE
India's Blue Economy: Untapped Potential in Ports, Fisheries and Ocean Resources
11 Nov 2026

India's Blue Economy: Untapped Potential in Ports, Fisheries and Ocean Resources

The maritime space of India, which comprises the coastline, island areas, a...

How Technology Is Making Waste Management More Efficient in Indian Cities
10 Nov 2026

How Technology Is Making Waste Management More Efficient in Indian Cities

Indian cities are adopting digital monitoring, sensors, and automated waste...

India's Cold Chain Logistics: The Backbone of Perishable Trade
9 Nov 2026

India's Cold Chain Logistics: The Backbone of Perishable Trade

India's cold chain network allows the transfer of perishables from farm...

Partners
Loading...